Molecular Diagnosis of Muscular Dystrophy Patients in Western Indian Population: A Comprehensive Mutation Analysis Using Amplicon Sequencing

Komal M. Patel1, Arpan D. Bhatt1, Krati Shah2, Bhargav N. Waghela1, Ramesh J. Pandit1, Harsh Sheth3, Chaitanya G. Joshi1 and Madhvi N. Joshi1*

1Gujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India, 2ONE-Centre for Rheumatology and Genetics, Vadodara, India, 3Foundation for Research in Genetics and Endocrinology (FRIGE), Ahmedabad, India

Muscular Dystrophies (MDs) are a group of inherited diseases and heterogeneous in nature. To date, 40 different genes have been reported for the occurrence and/or progression of MDs. This study was conducted to demonstrate the application of next-generation sequencing (NGS) in developing a time-saving and cost-effective diagnostic method to detect single nucleotide variants (SNVs) and copy number variants (CNVs) in a single test. A total of 123 cases clinically suspected of MD were enrolled in this study.

Amplicon panel-based diagnosis was carried out for 102 (DMD/BMD) cases and the results were further screened using multiplex ligation-dependent probe amplification (MLPA). Whilst in the case of LGMD (N = 19) and UMD (N = 2), only NGS panel-based analysis was carried out. We identified the large deletions in 74.50% (76/102) of the cases screened with query DMD or BMD. Further, the large deletion in CAPN3 gene (N = 3) and known SNV mutations (N = 4) were identified in LGMD patients. Together, the total diagnosis rate for this amplicon panel was 70.73% (87/123) which demonstrated the utility of panel-based diagnosis for high throughput, affordable, and time-saving diagnostic strategy. Collectively, present study demonstrates that the panel based NGS sequencing could be superior over to MLPA.

Keywords: next generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), duchenne muscular dystrophy (DMD), becker muscular dystrophy (BMD), limb-girdle muscular dystrophies, congenital muscular dystrophies (GMDs)

HIGHLIGHTS

- Muscular Dystrophies (MDs) are genetically heterogeneous diseases.
- Loss of function mutations in the DMD gene causes non-functional dystrophin protein that progresses various MDs.
- The customized amplicon panel consisting of genes targeting 29 MDs was used to detect large deletions in the DMD gene and novel deletion in the CAPN3 gene.
- NGS-based study provides eligibility of patients for currently available treatment such as exon skipping.
INTRODUCTION

Muscular dystrophy is a genetically heterogeneous group of neuromuscular diseases that result in degradation of skeletal muscles, progressive muscle weakness, loss of ambulation, cardiac attack, and respiratory failure (Wang et al., 2019). To date, more than 30 different types of MDs are known and can be classified based on the onset of disease, clinical manifestations, mode of inheritance, and severity of the disease (Gaina et al., 2019). Duchenne Muscular Dystrophy (OMIM # 310200) is the most common, rapidly progressive, and severe neuromuscular disease. It inherits in an X-linked recessive manner affecting 1 in 3,500 male children with onset before 5 years’ age (Wu et al., 2017; Mohammed et al., 2018; Kong et al., 2019; Wang et al., 2019). The DMD (dystrophin) is a large gene encompassing 79 exons and spanning approximately 2.5 Mb of the genomic DNA. Loss of function mutations in the DMD gene causes an impaired dystrophin protein which disturbs the membrane complex and myofiber loss. In contrast, patients with BMD have a shorter or less functioning form of the dystrophin protein, which makes the disease less severe and slow progressive (Wicklund, 2013; Wu et al., 2017; Wang et al., 2019). DMD and BMD are caused due to various mutations like large deletions (60%), SNVs and INDELs (30%), and duplications in the DMD gene (5–7%) (Mohammed et al., 2018; Wang et al., 2019).

Limb-Girdle Muscular Dystrophies (LGMDs) are another heterogeneous group of MDs consisting of around 30 subtypes, vary with genetic and clinical characteristics (Iyadurai and Kissel, 2016). LGMDs are progressive and characterized by weakness of the shoulder and pelvic girdle muscles. The incidence rate of LGMDs is approximately 1 in 14,500 to 123,000 (Pegoraro and Hoffman, 2012; Murphy and Straub, 2015; Nallamilli et al., 2018) [https://rarediseases.org/rare-diseases/limb-girdle-muscular-dystrophies, last accessed July 29, 2020.] The inheritance pattern of LGMDs is both autosomal dominant (AD-LGMD) and autosomal recessive (AR-LGMD). AR-LGMDs are more frequent than AD-LGMDs. LGMD associated proteins includes dystrophin-glycoprotein complex (DGC) and play a pivotal role in membrane stability. The mutations in MD genes causes disturbance in DGC proteins that destabilizes the membrane and eventually muscle degradation (Murphy and Straub, 2015).

Congenital Muscular Dystrophies (CMDs) are another group of muscular dystrophies that are also heterogeneous and affect newborns with an incidence of 1:10,000 to 1:50,000. Common symptoms of CMDs include hypotonia, scoliosis, motor delay, and muscle weakness from birth or infancy. Moreover, mutation in multiple genes causes CMDs (Valencia et al., 2013).

Routinely, Multiplex Ligation Dependent Probe Amplification (MLPA) or array-CGH (aCGH) diagnostics tests are being used to detect large CNVs (Deletions/Duplications) in MDs (Zhang K. et al., 2019). The results of these diagnostic tests further requires targeted sequencing to detect SNVs in the DMD/BMD cases. In several cases in which large deletions can be a cause of LGMDs, an aCGH is an exclusive option (Zhang K. et al., 2019). Performing aCGH in all referred cases would be time consuming and expensive. In a developing country like India, cost-effective and a single screening approach to detect CNVs, and SNVs, can be a boon. Furthermore, variety of therapies for DMD patients are available and few are under development, which requires an utmost knowledge of breakpoints for deletions and targeted mutations. Hence, timely and precise diagnosis of MDs helps clinicians to enroll eligible patients for therapy. The diagnosis of specific subtype of MDs using Next-generation sequencing (NGS) can be a timely and affordable approach which improves clinical prognosis (Bello and Pegoraro, 2016; Okubo et al., 2016; Kong et al., 2019). Further, the NGS platforms also identified the novel variants as well as confirmation of hard-to-detect variants (Sheik and Yokota, 2020). Recent studies suggest that the utilization of a high-throughput method using NGS platform is more suitable for clinical diagnosis (Okubo et al., 2016; Aravind et al., 2019). Moreover, the detection of large duplications is a major challenge for single-point diagnostic strategy (Okubo et al., 2016). In the present study, a total of 123 subjects (including both patients and female carriers) with suspected MDs were evaluated using an amplicon-based panel for its diagnostic specificity to detect CNVs and SNVs. Results of CNV analysis for the DMD gene were compared with MLPA. Further, we aimed to identify CNVs and SNVs type of mutation with our customized amplicon panel for different types of muscular dystrophies.

MATERIALS AND METHODS

Sample Collection and Genomic DNA Isolation

A total of 123 unrelated patients suspected of MD [DMD/BMD (N = 82), LGMD (N = 19), and UMD (N = 2)] and possible carriers (N = 20) were enrolled in this study. These cases were recruited in the study through screening camps across the state of Gujarat by collaborative efforts of the Indian Muscular Dystrophy Society (IMDS), Rashtriya Bal Swasthya Karyakram, and Gujarat Biotechnology Research Centre (GBRC). Informed and written consent was derived from the patients and their relatives after Genetic counseling. We have included patients clinically suspected with DMD/BMD with the following indications 1) significantly high serum creatine phosphokinase (CPK- >200 U/L (Aujla and Patel, 2020); 2) difficulty in walking, waddling gait, toe walk, Gower’s sign or loss of ambulation; 3) and progressive muscle weakness. Patients with evident proximal muscle weakness mainly the shoulder girdle and pelvic were included in the study with query LGMD. Uncertain Muscular Dystrophies (UMDs) were included in the study for amplicon sequencing. Blood samples were collected in EDTA vacutainer in a standard blood collection setup. Genomic DNA was extracted from blood samples using the QIAamp DNA Blood Mini Kit (QIAGEN, Germany) as per the manufacturer’s instructions. DNA
quantitation was done on Qubit 4 Fluorometer (Thermo Fisher Scientific, IN) using dsDNA BR (broad range) assay kit (Thermo Fisher Scientific, IN). For the data analysis, the baseline was generated using amplicon sequencing of 10 healthy male controls.

**Customized Multi-Gene Panel**

In the present study, a custom Ion AmpliSeq™ Panel which covers DMD, SGCA, SGCB, SGCG, SGCD, CAPN3, ISPD, TCAP, TMEM43, TRIM32, FKRP, MYOT, POMT1, FKTN, POMT2, POMGNT1, DAG1, LMNA, ANO5, LAMA2, COL6A1, COL6A2, COL6A3, FHL1, DYSF, LARGE, TRAPPC11, and EMD genes which are reported earlier and significantly associated with different pathologies of muscular dystrophies was designed. The association of these genes with different phenotypic abnormalities of MDs has been indicated in <Supplementary Table S1>. The panel comprises a total of 1,312 amplicon primer pools targeting the coding and untranslated regions (UTRs) with 10bp flanking regions of the mentioned genes.

**Targeted Sequencing**

A total of 123 cases (includes 102 DMD/BMD/Carrier, 2 UMD, and 19 LGMD) were screened by targeted sequencing using a custom amplicon panel. For each sample, 50 ng of DNA was amplified with custom primer pools using Ion Ampliseq™ HiFi Mix (Thermo Fisher Scientific, IN). This was followed by partial digestion, adaptor + barcode ligation, and library amplification. Libraries were purified using AgencourtAMPure XP (Beckman Coulter, United States). Purified libraries were quantified by Qubit dsDNA HS assay kit (Thermo Fisher Scientific, IN) and then pooled in equimolar concentrations. Emulsion PCR of pooled and diluted libraries was carried out using the Ion OneTouch™ 2 System (Thermo Fisher Scientific, IN) followed by enrichment of-template-positive Ion Sphere™ Particles on an Ion OneTouch™ ES system (Thermo Fisher Scientific, IN). Sequencing was carried out on the Ion Proton™ and Ion S5™ systems using Ion PI and Ion 530 chips respectively, with an average depth of 80x.

**MLPA**

A total of 102 DMD/BMD/Carrier subjects were screened through MLPA for all exon deletions and duplications in the human DMD gene. MLPA was performed using SALSA MLPA kit P034/P035 (MRC-Holland, Netherlands) as per the manufacturer’s instructions. Fragment analysis was performed on the 3500xL Genetic Analyzer (Applied Biosystems, United States) and MLPA data were analysed using Coffalyser software (MRC-Holland, Netherlands).

**Analysis of Single Nucleotide Variants**

Analysis of the raw sequences was performed using Ion Torrent Suite software v5.12 on the Ion torrent server with the incorporated standard pipeline. Variant analysis pipeline includes, signal processing, base calling, quality score assignment, adaptor trimming, PCR duplicate removal, and read alignment to the human reference genome (hg19 genome build). Variants were identified with Torrent Variant Caller plugin software and the Coverage Analysis plugin software obtained coverage analysis. The poor quality and intronic mutations were discarded from the datasets. Annotation of the high-quality variants was performed using the Ion Reporter server system. Clinically known and reported variants like pathogenic or likely pathogenic were identified from the ClinVar database (Landrum et al., 2014). To check strand biases and sequencing errors in the variant calling, alignments were visualized and the presence of mutations in the datasets against the reference genome was confirmed using Integrative Genomics Viewer (IGV) (Robinson et al., 2011). Classification of variants was carried out as per the American College of Medical Genetics and Genomics recommendations (ACMG) for standard interpretation and reporting of sequence variations (Richards et al., 2015).

**Identification of Large Homozygous and Heterozygous Deletions**

For identification of large deletion/s, we used a CNV detection workflow available on the Ion Reporter Server system. For the CNV detection workflow, the base line was created using 10 healthy normal individual male samples. This baseline control was used as a reference to analyse CNV in patient samples and female carriers.

**Analysis of Reading Frame**

In the DMD gene, in-frame and out-of-frame mutation patterns were analyzed with a reading frame checker of online available DMD database [Leiden Muscular Dystrophy Pages. https://www.dmd.nl/, last accessed July 29, 2020.]

**RESULTS**

A total of 123 suspected MD patients and suspected female carriers were enrolled in the study. The mean age of onset for DMD and BMD cases was 13 and 22 years, respectively. Average CPK levels in clinically confirmed DMD and BMD cases were 6,551.08 U/L and 1,459.8 U/L, respectively. The normal range of CPK is 20–200 U/L (Aujla and Patel, 2020). The graph of CPK vs age is shown in Figure 1.

**The Large Deletion in DMD/BMD**

CNV analysis of the NGS data of suspected DMD and BMD cases revealed large deletions in 76/102 (74.5%) cases, which included 69 patients and 7 female carriers. As per the reading frame rule, considering only exon deletion, 63/102 (61.76%) and 13/102 (12.75%) cases were categorized into DMD and BMD, respectively. The majority of deletions (78.94%) were in the large deletion/s, we used a CNV detection workflow available on the Ion Reporter Server system. For the CNV detection workflow, the base line was created using 10 healthy normal individual male samples. This baseline control was used as a reference to analyse CNV in patient samples and female carriers.

**Analysis of Reading Frame**

In the DMD gene, in-frame and out-of-frame mutation patterns were analyzed with a reading frame checker of online available DMD database [Leiden Muscular Dystrophy Pages. https://www.dmd.nl/, last accessed July 29, 2020.]

**RESULTS**

A total of 123 suspected MD patients and suspected female carriers were enrolled in the study. The mean age of onset for DMD and BMD cases was 13 and 22 years, respectively. Average CPK levels in clinically confirmed DMD and BMD cases were 6,551.08 U/L and 1,459.8 U/L, respectively. The normal range of CPK is 20–200 U/L (Aujla and Patel, 2020). The graph of CPK vs age is shown in Figure 1.

**The Large Deletion in DMD/BMD**

CNV analysis of the NGS data of suspected DMD and BMD cases revealed large deletions in 76/102 (74.5%) cases, which included 69 patients and 7 female carriers. As per the reading frame rule, considering only exon deletion, 63/102 (61.76%) and 13/102 (12.75%) cases were categorized into DMD and BMD, respectively. The majority of deletions (78.94%) were in the distal hotspot region (Exon 42–55) and proximal hotspot deletions were between exon 2–19 (10.52%). Two patients showed very large deletion including both proximal and distal hotspot regions. No deletion was observed in exon 61–79. The results of CNV analysis (DMD gene) using the NGS panel were concordant with the results obtained using MLPA ([Supplementary Table S2](#)). The deletion pattern of all positive
cases is depicted in Figure 2. The largest deletion was seen in (exons 1 to 60 (P30) followed by exons 3 to 44 (P41), exons 3 to 42 (P46), and exons 3 to 41 (P55). In the proximal region, the most frequently deleted exon is 10 (10/76, 13.15%) followed by exon 3, and exon 4 (9/76, 11.84%), while in the distal region, the most common deleted exon is 49 (41/76, 53.94%), followed by exon 48 and exon 47 (37/76, 48.68%). Single exon deletion was observed in 9/76 (11.84%) patients, where the most common deletion was observed in exon 45 followed by exon 51. More than one exon deletion was identified in 67/76 patients (88.15%). The distribution of the mutation pattern is shown in Figure 3. In this study, exon 45 to 52 was identified as a major deletion hotspot region. Representative IGV tool image of large deletion is shown in Supplementary Figure S1.

The Large Deletion in LGMD
Amplicon sequencing analysis of 19 LGMD suspected cases revealed a homozygous deletion of exon 17 to 24 of the

![Figure 1](image1.png)  
**Figure 1** | The distribution of patient’s Age vs CPK value in which X-axis shows CPK value (U/L) of patients and Y-axis shows the age of DMD/BMD patients in our study.

![Figure 2](image2.png)  
**Figure 2** | Homozygous and heterozygous deletion (female carrier) pattern in DMD/BMD patients. The X-axis shows exon number of DMD gene and Y-axis shows the number of patients showing deletion in the study. The highest deletions frequency was found in exons 45–52.
It was further confirmed by visualizing in IGV (Supplementary Figure S2), which supports the results of CNV workflow. CAPN3 deletion results are consistent with the clinical presentation of LGMD type 2A disease.

**Single Nucleotide Variation**

MLPA and NGS (CNV) negative cases (N = 44) were further considered for SNV analysis where in patient P109, a pathogenic hemizygous mutation was found in the DMD gene. This mutation causes a premature translational stop signal at codon 4,729 (p. Arg1577*) of the DMD gene, which results in a disrupted protein product. Truncating variants in the DMD gene are known to be pathogenic as per the Clinvar database (Landrum et al., 2014). This variant previously has been reported in individuals affected with DMD (Mah et al., 2011; Yang et al., 2013). In the case of suspected LGMD, mutations in 3 different genes were identified in 4 patients (P99 and P100 are sisters). Two pathogenic mutations were observed in POMT1 (P83) and DYSF (P92) genes and other 3 VUS mutations were observed in LAMA2 (P60), and SGCB (P99 and P100) genes. SNV analysis also revealed a missense Variant of Uncertain Significance (VUS) in 1 UMD and 1 suspected LGMD case in COL6A2 (P52) and COL6A1 (P97) gene, respectively (Table 1) which causes Bethlem myopathy 1 (LGMD R22 Collagen6-related) disease as per the Clinvar database (Landrum et al., 2014).

**TABLE 1** | Summary of point mutations in LGMD and UMD cases identified using panel-based NGS sequencing.

| Patient ID | CPK total | Age | Locus | Location | Function | Exon | Gene-cDNA | ClinVar’s clinical significance | dbSNP ID | Clinical phenotypes of disease |
|------------|-----------|-----|-------|---------|----------|------|-----------|--------------------------------|----------|------------------------------|
| P52        | 95        | 40  | chr21: 47537326 | Exonic | missense | 11   | COL6A2-c.1012C>T | Uncertain significance | rs775751831 | LGMD R22 Collagen6-related/ Ullrich CMD type 1 |
| P60        | NA        | 9   | chr6: 129704300 | Exonic | missense | 35   | LAMA2-c.4993G>A | Uncertain significance | rs373997222 | CMD due to partial LAMA2 deficiency |
| P83        | 3,675     | 18  | chr9: 134397500 | Exonic | missense | 19   | POMT1-c.1958C>T | Pathogenic           | rs149682171 | LGMD R5 γ-sarcoglycan-related |
| P92        | 1,631     | 28  | chr2: 71788881 | Splice site | unknown | 23   | DYSF-c.2217-1G>T | Pathogenic           | rs886044379 | LGMD R2 dysferlin-related |
| P97        | 653       | 21  | chr21: 47419593 | Exonic | missense | 27   | COL6A1-c.1763C>T | Uncertain significance | rs759442615 | LGMD R22 Collagen6-related/ Ullrich CMD type 1 |
| P99        | 995       | 32  | chr4: 52895918 | Exonic | missense | 3    | SGCB-c.355A>T | Uncertain significance | rs762412447 | LGMD R4 β-sarcoglycan-related |
| P100       | 679       | 34  | chr4: 52895918 | Exonic | missense | 3    | SGCB-c.355A>T | Uncertain significance | rs762412447 | LGMD R4 β-sarcoglycan-related |
| P109       | 3,673     | 12  | chrX: 32398743 | Exonic | missense | 34   | DMD-c.4729C>T | Uncertain significance | rs863224999 | DMD |

DMD, Duchenne muscular dystrophy; LGMD, Limb-girdle muscular dystrophies; CMD, congenital muscular dystrophy; CPK, creatine phosphokinase; NA, not available.

Note, 2018 Note: LGMDs, were described according to new nomenclature proposed by ENMC, Consortium (Straub et al., 2013) and Bethlem myopathy was described as a type of LGMD (Angeli et al., 2018).
DISCUSSION

In this study, we showed the utility of an amplicon panel to detect CNVs and SNVs to diagnose a heterogeneous group of MDs in patients and carriers. The accurate diagnosis of different types of muscular dystrophies using a single method such as Sanger sequencing or MLPA is a big challenge due to the complex mutational spectrum. MLPA being a first-line test for the diagnosis of the most common type of MD (DMD/BMD), to detect SNVs sequencing is mandatory. However, Sanger sequencing of the large coding region becomes laborious as well as costly (Wang et al., 2014; Wei et al., 2014). Hence, NGS could be the better alternative in terms of cost, since per base sequencing cost has decreased drastically (Pareek et al., 2011). Also, in cases with LGMDs and CMDs, neuromuscular disease-specific panels at a lower cost can be beneficial in developing countries like India. Previously, many studies have been published for NGS-based approaches for MD (Lim et al., 2011; Wang et al., 2014; Wei et al., 2014; Alame et al., 2016). However, there are very few such studies reported for the Indian population (Aravind et al., 2019; Ganapathy et al., 2019; Polavarapu et al., 2019).

We customized an amplicon panel consisting of genes targeting 29 different types of muscular dystrophies. One of the major objectives of the present study was to detect point mutation and CNVs in suspected, DMD/BMD patients/carriers, LGMD, and CMD using an NGS-based amplicon panel. Our CNV results of the DMD gene are consistent with the MLPA results. Our findings support the idea that NGS-based diagnosis methods could be routinely employed as a single diagnostic screening method for the most frequent type of MDs. Further, different MDs can be characterized by genotype and phenotype correlation. Earlier reports highlighted the importance of respective mutations in DMD patients and their mutation-specific therapies (Kohli et al., 2020). Identification of mutation patterns in the Indian cohort could improve the therapeutic management. In the mutation analysis, deletion was observed almost in each exon of DMD gene except 61–79 exons, where some deletions are reported in very low frequency in Leiden Open Variation database (LOVD) (Aartsma-Rus et al., 2006). Such as deletions are exon 19–45 (P15), 10–19 (P27 and P108), 1–60 (P30), and in 3–41 (P55). Furthermore, two novel out-of-frame deletions (exon 8–30 in P38 and 46–55 in P61) observed in our study are not reported in the LOVD database. The majority of deletions were observed in the hotspot region of exon 45–52. Interestingly, during sample collection, three patients were enrolled phenotypically as a DMD patient, however, our results concluded them as BMD patients with the in-frame mutation. The variants were confirmed in reading frame checker of LOVD database (Takeshima et al., 1994). In SNV analysis, a nonsense variant (c.4729C>T in exon 34) was observed in the DMD gene in patient P109. This point mutation has been recorded in the LOVD database as a pathogenic variant, which leads to a premature termination codon (p. Arg1577*) and hence forms a truncated protein. Earlier report suggests that the patients with such mutation are affected with DMD (Esterhuizen et al., 2014). Further, we have found four SNVs, COL6A2-c.1012C>T, LAMA2-c.4993G>A, COL6A1-c.1763C>T, SGCB-c.355A>T, reported as VUS in Clinvar database due to their conflicting reports and prediction from various computational tools and require further characterizations. NGS analysis of LGMD patients for CNV analysis revealed a homozygous deletion in the CAPN3 gene in exon 17 to 24 which is already reported in our previous study (Bhatt et al., 2019).

Identification of the same mutation in 3 patients in the current study accelerates the proof of novel variants in our population. Mutation in the CAPN3 gene leads to the most common form of autosomal recessive LGMD-2A type of Muscular Dystrophy. Deletion in 17–24 exons results in short truncated non-functional CAPN3 protein (Bhatt et al., 2019). CAPN3 gene regulates the instruction for Calpain-3 enzyme production that enzyme found in sarcomeres structure of muscle cells which are the basic unit for muscle contraction (Kramerova et al., 2007).

Characterization of the mutational landscape in the population may increase the success of current therapeutics and may provide direction to develop novel drug candidates. Antisense oligonucleotide (AON)-mediated exon skipping approach is currently developed to restore reading frame rule which produces partially function protein in DMD patients. FDA approved drugs such as EXONDYS 51 and VYONDYS 53 are commercially available to treat the patient who has a confirmed mutation to skip exon 51 and 53 respectively [http://www.aetna.com/cpb/medical/data/900_999/0911.html, last accessed 29 July 2020.]. The limitation of the present study is the very low frequency of point mutations and therefore further sampling is required to validate such mutation with our panel. Moreover, from a total of 123 cases, no mutation is detected in 36 cases suggesting further testing is required for other neuromuscular diseases which may rule out in our panel.

CONCLUSION

In conclusion, our finding showed the NGS platform could be a future diagnostic tool for identifying disease-causing mutation/s in different Muscular dystrophies, which are currently diagnosed using multiple methods. The analysis of CNV in the DMD gene concludes that our custom panel is superior to the MLPA method. NGS-based diagnosis is not only time-saving but also cost-effective method when compared with traditional testing strategies.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories [https://www.ncbi.nlm.nih.gov/sra?linkname=bioproject_sra_all&from_uid=692346. Accession number is PRJNA692346.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Foundation for Research in Genetics and Endocrinology, Institute of Human Genetics. Written
informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

Cf and MJ: Conceptualization, Methodology, Supervision; KP and AB: Data curation, analysis and interpretation of data, Writing—Original draft preparation; RP, BW, and HS: Thoroughly editing of the manuscript and interpretation of data; KS: Genetic counselling of patients.

FUNDING

This work was funded by the Department of Science and Technology, Government of Gujarat. Grant Number is GBRC/ GOG/DST/JD1/HLT/2017-18/06.

ACKNOWLEDGMENTS

We are thankful to the patients and their families for registering themselves and providing consent for participation in this study. We also thank the Department of Science and Technology (DST), Government of Gujarat, Gandhinagar for the financial assistance. We would like to thank Mr. Bakulesh Nagar for helping us in the successful conduction of the screening camp. We would also want to thank Rashtriya Bal Swasthya Karyakram (RBSK) and the Indian Muscular Dystrophy Society (IMDS) for their contribution to camp conduction. We would also like to thank our lab mate, Ms. Mital Patel, for participating in camps and Dr. ApurvashinPuvvar who helped us get over any obstacles we faced during different phases of the study. We would also like to thank the Institute of Human Genetics for providing ethical committee approval for conducting research on muscular dystrophy.

REFERENCES

Aartsma-Rus, A., Van Deutkom, J. C., Fokkema, I. F., Van Ommen, G. J., and Den Dunnen, J. T. (2006). Entries in the Leiden Duchenne Muscular Dystrophy Mutation Database: an Overview of Mutation Types and Paradoxical Cases that Confirm the reading-frame Rule. Muscle Nerve. 34, 135–144. doi:10.1002/mus.20586

Aartsma-Rus, A., Ginjaar, I. B., and Bushby, K. (2016). The Importance of Genetic data; KS: Genetic counselling of patients. Thoroughly editing of the manuscript and interpretation of data; KS: Genetic counselling of patients.

AUTHOR CONTRIBUTIONS

Cf and MJ: Conceptualization, Methodology, Supervision; KP and AB: Data curation, analysis and interpretation of data, Writing—Original draft preparation; RP, BW, and HS: Thoroughly editing of the manuscript and interpretation of data; KS: Genetic counselling of patients.

FUNDING

This work was funded by the Department of Science and Technology, Government of Gujarat. Grant Number is GBRC/ GOG/DST/JD1/HLT/2017-18/06.

ACKNOWLEDGMENTS

We are thankful to the patients and their families for registering themselves and providing consent for participation in this study. We also thank the Department of Science and Technology (DST), Government of Gujarat, Gandhinagar for the financial assistance. We would like to thank Mr. Bakulesh Nagar for helping us in the successful conduction of the screening camp. We would also want to thank Rashtriya Bal Swasthya Karyakram (RBSK) and the Indian Muscular Dystrophy Society (IMDS) for their contribution to camp conduction. We would also like to thank our lab mate, Ms. Mital Patel, for participating in camps and Dr. ApurvashinPuvvar who helped us get over any obstacles we faced during different phases of the study. We would also like to thank the Institute of Human Genetics for providing ethical committee approval for conducting research on muscular dystrophy.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.770350/full#supplementary-material

Supplementary Figure S1 | Integrative Genomics Viewer (IGV) snapshot depicting a representative image of Ion Reporter software (v5.12) CNV analysis results in DMD gene where red bar showing the deleted region of exon 3-4 in the patient.

Supplementary Figure S2 | Integrative Genomics Viewer (IGV) snapshot depicting a representative image of Ion Reporter software (v5.12) CNV analysis results in CAPNS3 gene where red bar showing the deleted region of exon 17-24 in the patient.

Ganapathy, A., Mishra, A., Soni, M. R., Kumar, P., Sadagopan, M., Kanthi, A. V., et al. (2019). Multi-gene Testing in Neurological Disorders Showed an Improved Diagnostic Yield: Data from over 1000 Indian Patients. J. Neurol. 266, 1919–1926. doi:10.1007/s00415-019-09358-1

Ayadurai, S. J. P., and Kissel, J. T. (2016). The Limb-Girdle Muscular Dystrophies and the Dystrophinopathies. CONTINUUM: Lifelong Learn. Neurol. 22, 1954–1977. doi:10.1212/01.wnl.0000500000000406

Kohli, S., Saxena, R., Thomas, E., Singh, K., Bijarnia Mahay, S., Puri, R. D., et al. (2020). Mutation Spectrum of Dystrophinopathies in India: Implications for Therapy. Indian J. Pediatr. 87, 495–504. doi:10.1007/s12098-020-03286-z

Kong, X., Zhong, X., Liu, C., Cui, S., Yang, Y., and Kong, L. (2019). Genetic Analysis of 1051 Chinese Families with Duchenne/Becker Muscular Dystrophy. BMC Med. Genet. 20, 139. doi:10.1186/s12881-019-0873-0

Kramerova, I., Beckmann, J. S., and Spencer, M. J. (2007). Molecular and Cellular Basis of Calpainopathy (Limb Girdle Muscular Dystrophy Type 2A). Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1772, 128–144. doi:10.1016/j.bbadis.2006.07.002

Landrum, M. J., Lee, J. M., Riley, G. R., Jang, W., Rubinstein, W. S., Church, D. M., et al. (2014). ClinVar: Public Archive of Relationships Among Sequence Variation and Human Phenotype. Nucl. Acids Res. 42, D980–D985. doi:10.1093/nar/gkt1113

Lim, B. C., Lee, S., Shin, J.-Y., Kim, J.-I., Hwang, H., Kim, K. J., et al. (2011). Genetic Diagnosis of Duchenne and Becker Muscular Dystrophy Using Next-Generation Sequencing Technology: Comprehensive Mutational Search in a Single Platform. J. Med. Genet. 48, 731–736. doi:10.1136/jmedgenet-2011-100133

Maj, J. K., Selby, K., Campbell, C., Nadeau, A., Tarnopolsky, M., McCormick, A., et al. (2011). A Population-Based Study of Dystrophin Mutations in Canada. Can. J. Neurol. Sci. 38, 465–474. doi:10.1017/S0317167110011896

Mohammed, F., Elshafey, A., Al-Baloos, H., Alaboud, H., Al Ben Ali, M., Baqer, A., et al. (2018). Mutation Spectrum Analysis of Duchenne/Becker Muscular Dystrophy in 68 Families in Kuwait: The Era of Personalized Medicine. PLoS one 13, e0197205. doi:10.1371/journal.pone.0197205

Murphy, A. P., and Straub, V. (2015). The Classification, Natural History and Treatment of the Limb Girdle Muscular Dystrophies. Jnd 2, S7–S19. doi:10.3233/jnd-150105

Can. J. Neurol. Sci. 38, 465–474. doi:10.1017/S0317167110011896

Mohammed, F., Elshafey, A., Al-Baloos, H., Alaboud, H., Al Ben Ali, M., Baqer, A., et al. (2018). Mutation Spectrum Analysis of Duchenne/Becker Muscular Dystrophy in 68 Families in Kuwait: The Era of Personalized Medicine. PLoS one 13, e0197205. doi:10.1371/journal.pone.0197205

Murphy, A. P., and Straub, V. (2015). The Classification, Natural History and Treatment of the Limb Girdle Muscular Dystrophies. Jnd 2, S7–S19. doi:10.3233/jnd-150105
Nallamilli, B. R. R., Chakravorty, S., Kesari, A., Tannier, A., Ankala, A., Schneider, T., et al. (2018). Genetic Landscape and Novel Disease Mechanisms from a largeDMDcohort of 4656 Patients. Ann. Clin. Transl. Neurol. 5, 1574–1587. doi:10.1002/acn3.649

Okubo, M., Minami, N., Goto, K., Goto, Y., Noguchi, S., Miyashita, S., et al. (2016). Genetic Diagnosis of Duchenne/Becker Muscular Dystrophy Using Next-Generation Sequencing: Validation Analysis of DMD Mutations. J. Hum. Genet. 61, 483–489. doi:10.1038/jhg.2016.7

Pareek, C. S., Smoczynski, R., and Tretyn, A. (2011). Sequencing Technologies and NGS. Dermatoendocrinology 3, 87–91. doi:10.2147/den.v3i3.2094

Pegoraro, E., and Hoffman, E. P. (2012)."Limb-Girdle Muscular Dystrophy Overview – RETIRED CHAPTER. FOR HISTORICAL REFERENCE ONLY," in GeneReviews® [Internet]. Editors M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, G. Mirzaa, et al. (Seattle, WA: University of Washington, Seattle), 1993–2021.

Polavarapu, K., Preethish-Kumar, V., Sekar, D., Vengalil, S., Nashi, S., Mahajan, N. P., et al. (2019). Mutation Pattern in 606 Duchenne Muscular Dystrophy Children with a Comparison between Familial and Non-familial Forms: A Study in an Indian Large Single-center Cohort. J. Neurol. 266, 2177–2185. doi:10.1007/s00415-019-09380-3

Richards, S., Aziz, N., Aziz, N., Bale, S., Bick, D., Das, S., et al. (2015). Standards and Guidelines for the Interpretation of Sequence Variants: a Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–423. doi:10.1038/jmgm.2015.30

Robinson, J. T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., et al. (2011). Integrative Genomics Viewer. Nat. Biotechnol. 29, 24–26. doi:10.1038/nbt.1754

Sheikh, O., and Yokota, T. (2020). Advances in Genetic Characterization and Genotype-Phenotype Correlation of Duchenne and Becker Muscular Dystrophy in the Personalized Medicine Era. Jpn J 10 (3), 111. doi:10.3390/ jpm10030111

Straub, V., Murphy, A., Udd, B., Corrado, A., Aymé, S., Bönneman, C., et al. (2018). 229th ENMC International Workshop: Limb Girdle Muscular Dystrophies - Nomenclature and Reformed Classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul. Disorder. 28 (8), 702–710. doi:10.1016/j.nmd.2018.05.007

Takeshima, Y., Nishio, H., Narita, N., Wada, H., Ishikawa, Y., Ishikawa, Y., et al. (1994). Amino-terminal Deletion of 53% of Dystrophin Results in an Intermediate Duchenne-Becker Muscular Dystrophy Phenotype. Neurology 44 (9), 1648–1651. doi:10.1212/wnl.44.9.1648

Valencia, C. A., Ankala, A., Rhodzenizer, D., Bhide, S., Littlejohn, M. R., Keong, L. M., et al. (2013). Comprehensive Mutation Analysis for Congenital Muscular Dystrophy: a Clinical PCR-Based Enrichment and Next-Generation Sequencing Panel. PLoS one 8, e53083. doi:10.1371/journal.pone.0053083

Wang, D., Gao, M., Zhang, K., Jin, R., Lv, Y., Liu, Y., et al. (2019). Molecular Genetics Analysis of 70 Chinese Families with Muscular Dystrophy Using Multiplex Ligation-dependent Probe Amplification and Next-Generation Sequencing. Front. Pharmacol. 10, 814. doi:10.3389/fphar.2019.00814

Wang, Y., Yang, Y., Liu, J., Chen, X.-C., Liu, X., Wang, C.-Z., et al. (2014). Whole Dystrophin Gene Analysis by Next-Generation Sequencing: A Comprehensive Genetic Diagnosis of Duchenne and Becker Muscular Dystrophy. Mol. Genet. Genomics 289, 1013–1021. doi:10.1007/s00438-014-0847-z

Wei, X., Dai, Y., Yu, P., Qu, N., Lan, Z., Hong, X., et al. (2014). Targeted Next-Generation Sequencing as a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: A Multi-Population Diagnostic Study. Eur. J. Hum. Genet. 22, 110–118. doi:10.1038/ejhg.2013.82

Wicklund, M. P. (2013). The Muscular Dystrophies. CONTINUUM: Lifelong Learn. Neurol. 19, 1535–1570. doi:10.1212/01.cno.0000440659.41675.8b

Wu, B., Wang, L., Dong, T., Jin, J., Lu, Y., Wu, H., et al. (2017). Identification of a Novel DMD Duplication Identified by a Combination of MLPA and Targeted Exome Sequencing. Mol. Cyto. 10, 8–6. doi:10.1186/s13039-017-0301-0

Yang, J., Li, S. Y., Li, Y. Q., Cao, J. Q., Feng, S. W., Wang, Y. Y., et al. (2013). MLPA-based Genotype-Phenotype Analysis in 1053 Chinese Patients with DMD/ BMD. BMC Med. Genet. 14, 29–9. doi:10.1186/1471-2350-14-29

Zhang, K., Yang, X., Lin, G., Han, Y., and Li, J. (2019a). Molecular Genetic Testing and Diagnosis Strategies for Dystrophinopathies in the Era of Next Generation Sequencing. Clinica Chim. Acta 491, 66–73. doi:10.1016/j.cca.2019.01.014

Zhang, Y., Yang, W., Wen, G., Wu, Y., Jing, Z., Li, D., et al. (2019b). Application Whole Exome Sequencing for the Clinical Molecular Diagnosis of Patients with Duchenne Muscular Dystrophy: Identification of Four Novel Nonsense Mutations in Four Unrelated Chinese DMD Patients. Mol. Genet. Genomic Med. 7, e622. doi:10.1002/mgm3.622

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Patel, Bhatt, Shah, Waghela, Pandit, Sheth, Joshi and Joshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

ANO5 anoctamin 5
CAPN3 calpain 3
COL6A1 collagen type VI alpha 1 chain
COL6A2 collagen type VI alpha 2 chain
COL6A3 collagen type VI alpha 3 chain
DAG1 dystroglycan 1
DMD Duchenne Muscular Dystrophy
DYSF dystrophy-associated fer-1-like protein
EMD Emerin
FHL1 Four-and-a-Half Lim Domains 1
FKRP fukutin related protein
FKTN fukutin
ISPD isoprenoid synthase domain-containing protein
LMNA lamin A/C
LAMA2 laminin subunit alpha 2
LARGE LARGE xylosyl- and glucuronyltransferase 1
MYOT myotilin
NGS Next Generation Sequencing
POMT1 protein O-mannosyltransferase 1
POMT2 protein O-mannosyltransferase 2
POMGNT1 protein O-linked mannose N-acetylgalactosaminyltransferase 1
(beta 1,2-)
SGCA Sarcoglycan Alpha
SGCB Sarcoglycan Beta (43 kDa Dystrophin-Associated Glycoprotein)
SGCG Sarcoglycan Gamma
SGCD Sarcoglycan Delta
TCAP Titin-Cap associated protein
TMEM43 Transmembrane Protein 43
TRAPPC11 trafficking protein particle complex 11
TRIM32 tripartite motif containing 32
VUS Variants of Uncertain Significance